Evidence map›Paper›PMID 36740558›Full record

ArticleVaccine2023

Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.

Helena C Maltezou, Dimitrios Basoulis, Konstantinos Bonelis, Maria N Gamaletsou, Theodoros V Giannouchos, Eleni Karantoni, Αmalia Karapanou, Konstantinos Kounouklas, Maria Effrosyni Livanou, Maria Zotou and 10 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Investigating a middle‑step COVID‑19 unit in Greece.Experimental and therapeutic medicine · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Helena C MaltezouDirectorate of Research, Studies and Documentation, National Public Health Organization, Athens, Greece. Electronic address: maltezou.helena@gmail.com.
Dimitrios BasoulisPathophysiology Department, Medical School, National and Kapodistrian University of Athens, Greece.
Konstantinos BonelisSecond Department of Internal Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Maria N GamaletsouPathophysiology Department, Medical School, National and Kapodistrian University of Athens, Greece.
Theodoros V GiannouchosDepartment of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States.
Eleni KarantoniSecond Clinic of Internal Medicine, COVID-19 Department, 251 Hellenic Air Force General Hospital, Athens, Greece.
Αmalia KarapanouInfection Control Committee, Laiko General Hospital, Athens, Greece.
Konstantinos KounouklasSecond Clinic of Internal Medicine, COVID-19 Department, 251 Hellenic Air Force General Hospital, Athens, Greece.
Maria Effrosyni LivanouThird Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Sotiria General Hospital, Athens, Greece.
Maria ZotouThird Department of Internal Medicine and Infectious Diseases Unit, Korgialeneio-Benakeio Red Cross Hospital, Athens, Greece.
Vasiliki RaptiThird Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Sotiria General Hospital, Athens, Greece.
Panagiota StamouSecond Clinic of Internal Medicine, COVID-19 Department, 251 Hellenic Air Force General Hospital, Athens, Greece.
Dimitrios LoulakisThird Department of Internal Medicine and Infectious Diseases Unit, Korgialeneio-Benakeio Red Cross Hospital, Athens, Greece.
Kyriakos SouliotisFaculty of Social and Political Sciences, University of Peloponnese, Corinth, Greece; Health Policy Institute, Athens, Greece.
Maria ChiniThird Department of Internal Medicine and Infectious Diseases Unit, Korgialeneio-Benakeio Red Cross Hospital, Athens, Greece.
Periklis PanagopoulosSecond Department of Internal Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Garyfalia PoulakouThird Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Sotiria General Hospital, Athens, Greece.
Konstantinos N SyrigosThird Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Sotiria General Hospital, Athens, Greece.
Dimitrios HatzigeorgiouMedical Directorate, Hellenic National Defence General Staff, Athens, Greece.
Nikolaos V SipsasPathophysiology Department, Medical School, National and Kapodistrian University of Athens, Greece.
National and Kapodistrian University of Athens · GRHellenic Air Force · GRHellenic Red Cross · GRDemocritus University of Thrace · GRLaiko General Hospital of Athens · GRNational Public Health Organization · GRUniversity of Peloponnese · GRUniversity of South Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWe estimated vaccine effectiveness (VE) of full (booster) vaccination against severe outcomes in hospitalized COVID-19 patients during the Delta and Omicron waves.

methodsThe study extended from November 15, 2021 to April 17, 2022. Full vaccination was defined as a primary vaccination plus a booster ≥ 6 months later.

resultsWe studied 1138 patients (mean age: 66.6 years), of whom 826 (72.6 %) had ≥ 1 comorbidity. Of the 1138 patients, 75 (6.6 %) were admitted to intensive care unit (ICU), 64 (5.6 %) received mechanical ventilation, and 172 (15.1 %) died. There were 386 (33.9 %) fully vaccinated, 172 (15.1 %) partially vaccinated, and 580 (51 %) unvaccinated patients. Unvaccinated patients were absent from work for longer periods compared to partially or fully vaccinated patients (mean absence of 20.1 days versus 12.3 and 17.3 days, respectively; p-value = 0.03). Compared to unvaccinated patients, fully vaccinated patients were less likely to be admitted to ICU [adjusted relative risk (ARR: 0.49; 95 % CI: 0.29-0.84)], mechanically ventilated (ARR: 0.43; 95 % CI: 0.23-0.80), and die (ARR: 0.57; 95 % CI: 0.42-0.78), while they were hospitalized for significantly shorter periods (ARR: 0.79; 95 % CI: 0.70-0.89). The adjusted full VE was 48.8 % (95 % CI: 42.7 %-54.9 %) against ICU admission, 55.4 % (95 % CI: 52.0 %-56.2 %) against mechanical ventilation, and 22.6 % (95 % CI: 7.4 %-34.8 %) against death. For patients with ≥ 3 comorbidities, VE was 56.2 % (95 % CI: 43.9 %-67.1 %) against ICU admission, 60.2 % (95 % CI: 53.7 %-65.4 %) against mechanical ventilation, and 43.9 % (95 % CI: 19.9 %-59.7 %) against death.

conclusionsFull (booster) COVID-19 vaccination conferred protection against severe outcomes, prolonged hospitalization, and prolonged work absenteeism.

Indexed as

AbsenteeismCOVID-19AgedCOVID-19 VaccinesGreeceHumansVaccinationCOVID-19 VaccinesAbsenteeismBoosterCOVID-19HospitalizationVaccine effectiveness

Identifiers

PMID36740558
PMCPMC9892328
OpenAlexW4319019645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.